Noticias y Actividades de Phathom Pharmaceuticals

Phathom Pharmaceuticals es una de las ...

• Russell 3000;
• TOB Iconic 10,000.

Phathom Pharmaceuticals es una empresa que cotiza bajo el símbolo de cotización PHAT (US).

Ver el organigrama con sus 27 ejecutivos principales

Biografías más buscadas en Phathom Pharmaceuticals

• Steven Basta, President and Chief Executive Officer and Director
• Frank Karbe, Director
• Asit Parikh, Director

Recientes movimientos de ejecutivos en Phathom Pharmaceuticals

• Ted Schroeder, se ha incorporado a la empresa como Director  (noticia publicada el 17 de abril de 2025).
• Terrie Curran, Director and Chief Executive Officer, ha dejado la empresa  (noticia publicada el 1 de abril de 2025).
• Steven Basta, se ha incorporado a la empresa como President and Chief Executive Officer and Director  (noticia publicada el 1 de abril de 2025).

Crear su alerta
para seguir los movimientos de los ejecutivos en Phathom Pharmaceuticals.

Phathom Pharmaceuticals tiene 1.831 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Eli Lilly (Estados Unidos).

Popular M&A news in Farmacia

• Chimerix and Chimerix have merged  (publicado el 22 de abril de 2025)..
• Imbria Pharmaceuticals acaba de anunciar una recaudación de fondos de 58 millones de dólares. (publicado el 10 de abril de 2025).
• Clario ha NRx Pharmaceuticals adquirido (publicado el 18 de marzo de 2025).

Otros contactos sugeridos en el sector Farmacia

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets en Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer en Adare Pharmaceuticals
• Seth Harrison - Chairman and Director en Braeburn Pharmaceuticals

Saber más sobre el sector Farmacia

Últimos comunicados de prensa de Phathom Pharmaceuticals

• Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates | Phathom Pharmaceuticals, Inc.
• Phathom Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference | Phathom Pharmaceuticals, Inc.
• Phathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis | Phathom Pharmaceuticals, Inc.
• Phathom Pharmaceuticals Presents Data on Novel Potassium-Competitive Acid Blocker (PCAB) Vonoprazan from a Range of Studies at Digestive Disease Week® (DDW) 2022 | Phathom Pharmaceuticals, Inc.
• Phathom Pharmaceuticals to Present Data at DDW 2022 Annual Meeting | Phathom Pharmaceuticals, Inc.
• Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates | Phathom Pharmaceuticals, Inc.
• Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital | Phathom Pharmaceuticals, Inc.
• Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults | Phathom Pharmaceuticals, Inc.
• View more press releases Close

Redes sociales sobre Phathom Pharmaceuticals

• Phathom Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
• Phathom Pharmaceuticals en LinkedIn, Twitter y YouTube